tbuckley/cabot-search huggingface dataset:
CAUSES OF CARDIOVASCULAR HOSPITALIZATION AND DEATH IN THE TAFAMIDIS IN TRANSTHYRETIN CARDIOMYOPATHY CLINICAL TRIAL (ATTR-ACT)
Authors: Alan B. Miller, James Januzzi, Blair J. O'Neill, Balarama Gundapaneni, Terrell A. Patterson, Marla B. Sultan, Jose Lopez-Sendon
Journal: Journal of the American College of Cardiology (2020)
Smarcad1 mediates microbiota-induced inflammation in mouse and coordinates gene expression in the intestinal epithelium
Authors: Juri Kazakevych, Jérémy Denizot, Anke Liebert, Mariana Portovedo, Mia Mosavie, Payal Jain, Claudia Stellato, Claire Fraser, Renan Oliveira Corrêa, Marina Célestine, Raphaël Mattiuz, Hanneke Okkenhaug, J. Ross Miller, Marco Aurélio Ramirez Vinolo, Marc Veldhoen, Patrick Varga-Weisz
Journal: Genome biology (2020)

How intestinal epithelial cells interact with the microbiota and how this is regulated at the gene expression level are critical questions. Smarcad1 is a conserved chromatin remodeling factor with a poorly understood tissue function. As this factor is highly expressed in the stem and proliferative zones of the intestinal epithelium, we explore its role in this tissue.Specific deletion of Smarcad1 in the mouse intestinal epithelium leads to colitis resistance and substantial changes in gene expression, including a striking increase of expression of several genes linked to innate immunity. Absence of Smarcad1 leads to changes in chromatin accessibility and significant changes in histone H3K9me3 over many sites, including genes that are differentially regulated upon Smarcad1 deletion. We identify candidate members of the gut microbiome that elicit a Smarcad1-dependent colitis response, including members of the poorly understood TM7 phylum.Our study sheds light onto the role of the chromatin remodeling machinery in intestinal epithelial cells in the colitis response and shows how a highly conserved chromatin remodeling factor has a distinct role in anti-microbial defense. This work highlights the importance of the intestinal epithelium in the colitis response and the potential of microbial species as pharmacological and probiotic targets in the context of inflammatory diseases.
CHANGES OF LEFT ATRIAL APPENDAGE ORIFICE FOLLOWING PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE USING THREE-DIMENSIONAL ECHOCARDIOGRAPHY
Authors: Xochitl Ortiz-Leon, Edith Posada, Wanwen Chen, Alda Bregasi, Ian Crandall, Jason Pereira, Juan Betuel Ivey Miranda, Joseph Akar, Ben A. Lin, Robert McNamara, James Freeman, Jeptha P. Curtis, José Antonio Arias-Godínez, Lissa Sugeng
Journal: Journal of the American College of Cardiology (2020)
Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells
Authors: Sharon M. Sagnella, Lu Yang, Gemma E. Stubbs, Ebru Boslem, Estefania Martino-Echarri, Katarzyna Smolarczyk, Stacey L. Pattison, Natasha Vanegas, Eva St. Clair, Stephen Clarke, John Boockvar, Jennifer A. MacDiarmid, Himanshu Brahmbhatt
Journal: Cancer Cell (2020)
Patient and caregiver satisfaction with ambulatory oncology care: Agreement and predictors.
Authors: Breffni Hannon, Chami Jayasuriya, Nadia Swami, Lisa Le, Camilla Zimmermann, Gary Rodin
Journal: Journal of Clinical Oncology (2012)

e16567 Background: Little is known about the level of agreement between patient and caregiver individual reports of satisfaction with healthcare, and no such study has been conducted in the advanced cancer setting. Our aims were to assess the level of agreement in satisfaction with oncology care, between patients with advanced cancer and their caregivers, and to identify factors associated with satisfaction. Methods: Patients with advanced cancer and their caregivers were recruited from ambulatory oncology clinics. Satisfaction with care was measured using FAMCARE- patient and caregiver versions. Patients completed measures of symptom severity (ESAS) and quality of life (FACT-G, FACIT-Sp). Caregivers completed a quality of life measure (CQOL-C). Agreement between patient and caregiver satisfaction scores was assessed using ICC and weighted kappa statistics; multivariable regression was used to determine individual predictors of satisfaction. Results: For the 191 patient-caregiver pairs, caregivers were less satisfied than patients (mean FAMCARE score 67.5 vs. 65.7 out of a possible 90, p=0.02). Overall agreement between patients and caregivers was moderate (ICC = 0.59). Agreement for individual items on FAMCARE was low (kappa range = 0.11-0.37). Both patients and caregivers were least satisfied with information on managing pain and information regarding prognosis. Factors associated with patient satisfaction were lower education level, better quality of life, and less symptom severity; caregiver satisfaction was associated with lower education levels, and better quality of life. Conclusions: Despite considerable discrepancy between caregiver and patient ratings, there was agreement regarding which elements of care needed most improvement. Greater attention to pain control and communication regarding prognosis would further improve patient and caregiver satisfaction with care in advanced cancer
LONG-TERM ADVERSE ISCHEMIC OUTCOMES AFTER PERCUTANEOUS CORONARY INTERVENTION AMONG PATIENTS BY PRIOR CORONARY ARTERY BYPASS GRAFTING STATUS: ANALYSIS FROM 19 RANDOMIZED TRIALS
Authors: Nicholas Varunok, Mahesh Madhavan, Bjorn Redfors, Jamie Diamond, Pieter Smits, Clemens von Birgelen, Mengdan Liu, Patrick Serruys, Ori Ben-Yehuda, Ajay Kirtane, Martin Leon, Gregg Stone
Journal: Journal of the American College of Cardiology (2020)
Targeting Myeloid-Specific Integrin α9β1 Improves Short- and Long-Term Stroke Outcomes in Murine Models With Preexisting Comorbidities by Limiting Thrombosis and Inflammation
Authors: Nirav Dhanesha, Manish Jain, Amit K. Tripathi, Prakash Doddapattar, Mehul Chorawala, Girish Bathla, Manasa K. Nayak, Madankumar Ghatge, Steven R. Lentz, Shigeyuki Kon, Anil K. Chauhan
Journal: Circulation Research (2020)

Currently, there is no effective intervention available that can reduce brain damage following reperfusion. Clinical studies suggest a positive correlation between the increased influx of neutrophils and severity of brain injury following reperfusion. Integrin α9β1 is highly expressed on activated neutrophils and contributes to stable adhesion, but its role in stroke outcome has not been demonstrated to date.
YIA20-002: Racial Differences in Clinical Histopathological Features and Survival of Early- and Average-Onset Colorectal Cancer
Authors: Hanyu Chen, Jie Liu, Xiaoyu Zong, Ai Zhang, Jennifer Tappenden, Thomas Walsh, Deyali Chatterjee, Ryan Courtney Fields, Graham Andrew Colditz, Yin Cao
Journal: Journal of the National Comprehensive Cancer Network (2020)
Phase II trial of preoperative (POP) irinotecan (I) + cisplatin (C) and radiotherapy for esophageal cancer
Authors: A. L. Visbal, G. Darling, R. Wong, M. Guindi, J. Hornby, R. Feld, J. Ringash, S. Keshavjee, E. Chen, J. Brierly, J. Knox
Journal: Journal of Clinical Oncology (2006)

4056 Background: Esophagectomy (E) for locally advanced esophageal cancer (LAEC) yields limited survival; this phase II trial assess feasibility and efficacy of induction chemo-radiotherapy followed by E. Methods: Patients (pts) with LAEC of the thoracic esophagus (TE) or gastroesophageal junction (GEJ), ECOG PS ≤ 2 and surgical candidates underwent POP I (65mg/m 2 ) + C (30mg/m 2 ) on weeks 1,2,4,5,7,8 + concurrent conformal radiotherapy (40Gy/20 fractions (F) during wk 4–7) and external beam boost (10Gy/5F on wk 8); E was performed on wk 12–16 after restaging. Pts receiving 75% of POP chemotherapy were eligible for pathologic (p) evaluation; planned sample size 36 nonM1A pts. Results: 52 pts enrolled from 11/02 to 12/05, mean age 60 yr (33–79), male:40, GEJ:TE/15:37; 37 adenocarcinoma, 13 SCC, 2 other; 13 pts were stage IIA, 7 IIB, 22 III, and 10 IVA. Toxicity during POP treatment included ANC (G3/4:36%), febrile neutropenia (9%), diarrhea (G3:9%), nausea (G3:6%), esophagitis (G3:2%) and anorexia (G3/4:15%); 3 pts stopped treatment due to toxicity, 2 withdrew, 2 progressed becoming non-operable, 1 died of a stroke and 1 from central line sepsis. Clinical response by RECIST was CR:2%, PR:30%, SD:62% and PD in 6%. Dysphagia improved or resolved in 34/47 pts (72%) during POP treatment. Of 43 evaluable pts, 41 underwent E, achieving R0 resection in 98% (1 refused E, 1 pending). Perioperative complications included anastomotic leak (23%), Afib (21%), pneumonia (21%), delirium (10%) and aspiration (10%); 1 pt died from aspiration. 7 pts (17%) achieved pCR, 2 of whom were pretreatment clinical stage IIA, 1 IIb and 4 III; downstaging occurred in 3/7 pts; 15 pts (36.6%) achieved minimal residual disease, 15 (36.6%) pPR, and 4 (9.8%) pSD. At a median (med) follow-up of 15.2 months (1.3–34.5m), 16/52 patients died (med &amp; 2yr overall survival (OS) of 29 m &amp; 66%). Of 41 resected pts, 17 recurred (med &amp; 2yr disease free survival (DFS) of 20m &amp; 46%) of whom 10 died of progression (med &amp; 2-yr OS of 29m &amp; 68.4%). 2yr DFS &amp; OS was 83% &amp; 86% in pCR vs 41% &amp; 76% in non-pCR. Conclusion: In LAEC, induction I/C and radiotherapy followed by E is associated with 72% dysphagia improvement, a significant but manageable toxicity profile, and encouraging survival compared to historical controls. [Table: see text]
TO BLEED OR TO CLOT: STROKE PREVENTION STRATEGIES IN PATIENTS WITH ATRIAL FIBRILLATION OR FLUTTER AFTER BLEEDING
Authors: Sarah Gorgis, Guneet Ahluwalia, Aeman Hana, Georgi Fram, Mohammed Dabbagh, Dilshan Dhillon, Ahmad Murad, Arfaat Khan, William W. O'Neill, Scott Kaatz, Dee Dee Wang
Journal: Journal of the American College of Cardiology (2020)
Molecular profiling and comparative genomic hybridization analysis in human melanoma cell lines and identification of BRAF amplification in a PLX4032 acquired resistance cell line.
Authors: Erika Maria Von Euw, Judy Dering, Lee Anderson, Charles Ginther, Hsiao-Wang Cheng, Ke-Wei Gong, Veerauo V Konkankit, Richard S. Finn, Dennis J. Slamon
Journal: Journal of Clinical Oncology (2012)

8592 Background: Melanoma is the most aggressive form of skin cancer. Its management is evolving rapidly due to an improved understanding of the molecular heterogeneity and the development of effective, personalized targeted therapies. PLX4032 is a BRAF inhibitor that induces tumor response in patients with BRAF mutation whose response is limited due to acquired resistance. We used comprehensive microarray and genomic analysis to molecularly characterize a panel of melanoma cell lines with the goal of identifying new molecular subgroups. To better understand the mechanisms of acquired resistance to PLX4032, we included two cell lines that were conditioned in vitro to acquire resistance. Methods: Using microarray, we studied 52 melanoma cell lines for mRNA expression and performed array CGH using genome microarrays. Data analysis was done using Rosetta Resolver and Agilent Analytics 4.0 software. Results: Microarray analysis suggests melanoma is comprised of at least two distinct molecular groups. One group has a differentiated melanocyte phenotype and the other has an expression signature characteristic of progenitor-like cells. The progenitor-like group expresses SOX9, WNT5A and WNT5B and also has the lowest relative expression of MITF. The most differentiated group had the highest MITF and SOX5 levels, while the progenitor-like cell lines have decreased expression. MITF appears to be a strong candidate marker for this group. Positive correlation exists between MITF expression levels and gene copy number, as almost all of the MITF samples amplified by CHG analysis are also overexpressed. A third group shows strong expression of SOX5, SOX10 and Nestin. One of the most important findings is M14-R cell line, conditioned to acquire PLX4032 resistance, has a focal, high level amplification of BRAF (Log2 ratio = 3, 8-fold amplification) when compared with the parental cell line, which is extremely sensitive to PLX4032. Conclusions: These results afford new insight into the potential pathogenesis and classification and provide a greater understanding of melanoma. BRAF amplification could be a novel mechanism of resistance to PLX4032.
FEATURE TRACKING MYOCARDIAL STRAIN INCREMENTALLY IMPROVES PROGNOSTICATION IN MYOCARDITIS BEYOND TRADITIONAL CMR FEATURES
Authors: Christoph Gräni, Kady Fischer, Sarah J. Obrist, Sophie A. Erne, Anselm W. Stark, Kyoichi Kaneko, Dominik P. Guensch, Adrian T. Huber, Simon Greulich, Ayaz Aghayev, Michael L. Steigner, Ron Blankstein, Raymond Y. Kwong
Journal: Journal of the American College of Cardiology (2020)
Nuclear Y-box binding protein-1 expression as a prognostic marker and correlation with epidermal growth factor receptor expression in cervical cancer.
Authors: Shin Nishio, Kimio Ushijima, Shuji Takemoto, Yuko Sasajima, Hitoshi Tsuda, Takahiro Kasamatsu, Toshiharu Kamura
Journal: Journal of Clinical Oncology (2012)

5085 Background: Y-box binding protein-1 (YB-1) is a member of the cold shock protein family and functions in transcription and translation. Many reports indicate that YB-1 is highly expressed in tumor cells and is a marker of tumor aggressiveness and clinical prognosis. Overexpression of epidermal growth factor receptor (EGFR) has been associated with poor outcomes in cervical cancer (CC). Clinical trials have shown that EGFR inhibitors are effective against CC (JCO 2011). Nuclear YB-1 expression correlates with EGFR expression in various types of cancer. Methods: Nuclear YB-1 expression was immunohistochemically analyzed in tissue specimens obtained from 204 CC patients who underwent surgery. Associations of nuclear YB-1 expression with clinicopathological factors such as survival and EGFR (HER1 and HER2) expression were investigated. Results: Nuclear YB-1 expression was observed in 41 (20%) of 204 cases and correlated with stage, tumor diameter, stromal invasion, and lymph-node metastasis. Nuclear YB-1 expression also correlated with both HER1 expression (p=0.0114) and HER2 expression (p=0.0053). Kaplan-Meier survival analysis showed that nuclear YB-1 expression was significantly associated with poor outcomes in terms of progression-free survival (p=0.0033) and overall survival (p=0.0003). On multivariate analysis, stromal invasion, parametrial invasion, and nuclear YB-1 expression were independent predictors of survival. Conclusions: Nuclear YB-1 expression is a prognostic marker and correlates with EGFR expression in CC.
MORTALITY AT 30 DAYS FOLLOW UP IN NATIVE AORTIC REGURGITATION PATIENTS TREATED WITH TAVR: META-ANALYSIS OF 1,221 PROCEDURES
Authors: Rajkumar P. Doshi, Ashish Kumar, Igor Pedreira Vaz, Devina Adalja, Jay Shah, Monil Majmundar, Nageshwara Gullapalli
Journal: Journal of the American College of Cardiology (2020)
Budgeting for covid-19: changing the narrative and narrating the change
Authors: Andy Cowper
Journal: BMJ (2020)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Budgeting for covid-19: changing the narrative and narrating the change Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Eleven faces of coronavirus disease 2019
Authors: Xiang Dong, Yi‐yuan Cao, Xiao‐xia Lu, Jin‐jin Zhang, Hui Du, You‐qin Yan, Cezmi A. Akdis, Ya‐dong Gao
Journal: Allergy (2020)

Abstract Background and aims The outbreak of coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection has recently spread worldwide and been declared a pandemic. We aim to describe here the various clinical presentations of this disease by examining eleven cases. Methods Electronic medical records of 11 patients with COVID‐19 were collected, and demographics, clinical manifestations, outcomes, key laboratory results, and radiological images are discussed. Results The clinical course of the eleven cases demonstrated the complexity of the COVID‐19 profile with different clinical presentations. Clinical manifestations range from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia. Laboratory detection of the viral nucleic acid can yield false‐negative results, and serological testing of virus‐specific IgG and IgM antibodies should be used as an alternative for diagnosis. Patients with common allergic diseases did not develop distinct symptoms and severe courses. Cases with a pre‐existing condition of chronic obstructive pulmonary disease or complicated with a secondary bacterial pneumonia were more severe. Conclusion All different clinical characteristics of COVID‐19 should be taken into consideration to identify patients that need to be in strict quarantine for the efficient containment of the pandemic.
Gefitinib combined biologic therapy for advanced lung adenocarcinoma.
Authors: Baoping Li, Lei Zhang
Journal: Journal of Clinical Oncology (2013)

e19098 Background: Gefitinib is an effective treatment for non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations. However, due to the limited genetic testing methods and other constraints, a large proportion of patients did not benefit from it. In order to overcome the limitation of genetic testing and other constraints, we use gefitinib with the immune-biotherapy to treatment advanced lung adenocarcinoma. Methods: From February 2011 to December 2012, we use gefitinib combined with immune-therapy to treat 59 cases with advanced lung adenocarcinoma. These patients completes at least one cycle of therapy. The efficacy and quality of life were investigated. The prognostic factors were analyzed using Cox regression model. Results: CRF0, PR:46, SD:13, the PD:0. The overall response rate = 77.97%. FACT-L: 100%. The response rate and scores of quality of life are higher than the reported data. COX regression analysis showed that the complete remission after the treatment is significant factor(P &lt;0.01), but the factors such as the disease control status, gender, tumor stage, smoking history were not significant. Conclusions: Gefitinib and biological therapy combined, can significantly improve short-term effect of advanced lung adenocarcinoma. Its possible mechanism of gefitinib to reduce interstitial fluid pressure may increase immunocompetent cells into the tumor tissues, thereby enhancing efficacy.
CARDIOVASCULAR AND CEREBROVASCULAR EVENTS AMONG PATIENTS RECEIVING IMMUNE CHECKPOINT INHIBITORS
Authors: Raza Alvi, Zsofia Drobni, Amna Zafar, Lili Zhang, Jana Taron, Daniel Zlotoff, Adam Rokicki, Vineet K. Raghu, Rayma C. Mosarla, Sean Murphy, Paula K. Rambarat, Ryan Sullivan, Kerry L. Reynolds, Udo Hoffmann, Tomas G. Neilan
Journal: Journal of the American College of Cardiology (2020)
PROGNOSTIC VALUE OF PERI-CORONARY ADIPOSE TISSUE ATTENUATION AND PHENOTYPIC CLUSTERING OF WHOLE VESSEL AND LESION PLAQUE QUANTIFICATION ON CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY
Authors: Masahiro Hoshino, Tomoyo Sugiyama, Yoshihisa Kanaji, Masao Yamaguchi, Masahiro Hada, Yohei Sumino, Hidenori Hirano, Misawa Toru, Tomoki Horie, Kai Nogami, Hiroki Ueno, Taishi Yonetsu, Tsunekazu Kakuta
Journal: Journal of the American College of Cardiology (2020)
Outcomes of small call carcinoma of bladder in elderly.
Authors: Swapna Thota, Gaurav Kistangari, Rohan Garje, Hamed Daw
Journal: Journal of Clinical Oncology (2012)

e15023 Background: Small cell carcinoma (SCCB) is an aggressive tumor and presents in an advanced stage. In this retrospective study we analyze the patterns of treatment and survival among elderly patients (age&gt;75 years). Methods: We identified 38 patients who were diagnosed with primary SCCB at our institution and its affiliated hospitals between 1995-2010. Out of which 15 patients were above the age of 75 years. For each patient histological, demographic and clinical data were obtained by chart review. Deaths of all patients were confirmed by social security death index (SSDI). Staging of all patients were categorized as limited (T1-4N0-1M0) or extensive stage (TxNxM1 or TxN2-3M0). Results: 15 patients were identified with pure small cell carcinoma of bladder. Mean age of patients was 80 years ( ranged from 76 years to 90 years). Male to female ratio was 5:1. 86% were caucasians. Among patients with available clinical information, 5 out of 15 patients (33.3%) had extensive stage and remaining 10 had limited stage SCCB. Around 73% (11/15) of the patients underwent transurethral resection of bladder tumor (TURBT). One patient had partial cystectomy and three patients had radical cystectomy. All three pateints who underwent radical cystectomy had limited disease and had an overall median survival (OMS) of 27 months. Patients with TURBT had a OMS of 6 months. Conclusions: Prognosis for patients with SCCB remains poor. Careful selection of patients for radical cystectomy with limited disease may improve overall median survival among elderly population with SCCB.
MULTICENTER EVALUATION OF QUALITY OF LIFE IN PATIENTS WITH PARADOXICAL LOW-FLOW, LOW-GRADIENT UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT (PLO-FLOW TAVR STUDY)
Authors: Sameer Hirji, Tsuyoshi Kaneko, Siobhan McGurk, Olena Cherkasky, Hasan Ahmed, S. Chiu Wong, Arash Salemi, Polydoros Kampaktsis, Ryan Kaple, John Forrest, Annapoorna Subhash Kini, Alexandra Malarczyk, Spencer Kiehm, Edward Percy, Morgan Harloff, Farhang Yazdchi, Pinak Shah, Gilbert Tang
Journal: Journal of the American College of Cardiology (2020)
Cell‐Free Virus‐Host Chimera DNA From Hepatitis B Virus Integration Sites as a Circulating Biomarker of Hepatocellular Cancer
Authors: Chiao‐Ling Li, Ming‐Chih Ho, You‐Yu Lin, Sheng‐Tai Tzeng, Yun‐Ju Chen, Hsin‐Yung Pai, Ya‐Chun Wang, Chi‐Ling Chen, Yu‐Hsin Lee, Ding‐Shinn Chen, Shiou‐Hwei Yeh, Pei‐Jer Chen
Journal: Hepatology (2020)

Background and Aims Early recurrence of hepatocellular carcinoma (HCC) after surgical resection compromises patient survival. Timely detection of HCC recurrence and its clonality is required to implement salvage therapies appropriately. This study examined the feasibility of virus‐host chimera DNA (vh‐DNA), generated from junctions of hepatitis B virus (HBV) integration in the HCC chromosome, as a circulating biomarker for this clinical setting. Approach and Results HBV integration in 50 patients with HBV‐related HCC was determined by the Hybridization capture‐based next‐generation sequencing (NGS) platform. For individual HCC, the vh‐DNA was quantified by specific droplet digital PCR (ddPCR) assay in plasma samples collected before and 2 months after surgery. HBV integrations were identified in 44 out of 50 patients with HBV‐related HCC. Tumor‐specific ddPCR was developed to measure the corresponding vh‐DNA copy number in baseline plasma from each patient immediately before surgery. vh‐DNA was detected in 43 patients (97.7%), and the levels correlated with the tumor sizes (detection limit at 1.5 cm). Among the plasma collected at 2 months after surgery, 10 cases (23.3%) still contained the same signature vh‐DNA detected at baseline, indicating the presence of residual tumor cells. Nine of them (90%) experienced HCC recurrence within 1 year, supporting vh‐DNA as an independent risk factor in predicting early recurrence. Analysis of circulating vh‐DNA at recurrence further helped identify the clonal origin. A total of 81.8% of recurrences came from original HCC clones sharing the same plasma vh‐DNA, whereas 18.2% were from de novo HCC. Conclusions vh‐DNA was shown to be a circulating biomarker for detecting the tumor load in majority of patients with HBV‐related HCC and aided in monitoring residual tumor and recurrence clonality after tumor resection.
IMPACT OF SPECIALIZED CARDIAC UNITS ON ALL-CAUSE 30-DAY READMISSION RATES AMONG PATIENTS WITH HEART FAILURE
Authors: Jad Ballout, Mouin S. Abdallah, Corinne Bott-Silverman, Kathleen Kravitz, Tim Sobol, Randall C. Starling, Umesh Khot
Journal: Journal of the American College of Cardiology (2020)